Introduction

The emergence of a novel coronavirus, SARS-CoV-2, has highlighted the need for rapid, accurate, and point-of-care diagnostic testing. As of now, there is not enough testing capacity in the world to meet the stated testing targets, which are expected to skyrocket globally for broader testing during reopening

Aim

This review focuses on the development of lab-on-chip biosensing platforms for diagnosis of COVID-19 infection.

Results

We discuss advantages of utilizing lab-on-chip technologies in response to the current global pandemic, including their potential for low-cost, rapid sample-to-answer processing times, and ease of integration into a range of healthcare settings. We then highlight the development of magnetic, colorimetric, plasmonic, electrical, and lateral flow-based lab-on-chip technologies for the detection of SARS-CoV-2, in addition to other viruses. We focus on rapid, point-of-care technologies that can be deployed at scale, as such devices could be promising alternatives to the current gold standard of reverse transcription-polymerase chain reaction (RT-PCR) diagnostic testing.

Conclusion

This review is intended to provide an overview of the current state-of-the-field and serve as a resource for innovative development of new lab-on-chip assays for COVID-19 detection.

中文翻译：

---

片上实验室生物传感器支持可扩展的 COVID-19 检测。

介绍

新型冠状病毒 SARS-CoV-2 的出现凸显了对快速、准确和即时诊断测试的需求。截至目前，世界上没有足够的测试能力来满足既定的测试目标，预计在全球范围内，这些目标将在重新开放期间进行更广泛的测试

目标

本综述侧重于开发用于诊断 COVID-19 感染的片上实验室生物传感平台。

结果

我们讨论了利用芯片实验室技术应对当前全球大流行的优势，包括它们在低成本、快速的样本到答案处理时间以及易于集成到一系列医疗保健环境中的潜力。然后，我们重点介绍了用于检测 SARS-CoV-2 以及其他病毒的磁性、比色、等离子、电和横向流动的芯片实验室技术的发展。我们专注于可以大规模部署的快速、即时技术，因为这些设备可能是目前逆转录聚合酶链反应 (RT-PCR) 诊断测试黄金标准的有希望的替代品。

结论

本综述旨在概述该领域的当前状态，并作为创新开发用于 COVID-19 检测的新型芯片实验室检测的资源。